Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $70.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 4.05% year-over-year to $70.0 million in Q1 2026; TTM through Mar 2026 was $70.0 million, a 4.05% decrease from a year earlier, with the FY2025 full-year figure at $71.8 million, down 15.98% from the prior year.
• Other Non-Current Liabilities slipped to $70.0 million in Q1 2026 per AMRX's latest filing, from $71.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $85.5 million in Q1 2024 and bottomed at $300000.0 in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $73.0 million (2025), against an average of $55.8 million.
• Across the five-year window, Other Non-Current Liabilities plunged 98.45% in 2023 and soared 28393.0% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $3.3 million in 2022, then tumbled by 90.88% to $300000.0 in 2023, then surged by 28393.0% to $85.5 million in 2024, then retreated by 15.98% to $71.8 million in 2025, then dropped by 2.5% to $70.0 million in 2026.
• Per Business Quant, the three latest AMRX Other Non-Current Liabilities figures stand at $70.0 million (Q1 2026), $71.8 million (Q4 2025), and $74.5 million (Q3 2025).